August 29, 2019 / 5:23 AM / 6 months ago

Roche's immunotherapy Tecentriq gets European nod for breast cancer

ZURICH, Aug 29 (Reuters) - Roche’s Tecentriq won European approval to be used against tough-to-treat triple-negative breast cancer, helping the Swiss drugmaker’s immunotherapy expand indications as it seeks to rival more-established medicines.

The European Commission approved Tecentriq with Abraxane for people with metastatic triple-negative breast cancer that tests positive for a protein believed to help the tumour evade attack by the body’s immune system, Roche said on Thursday. (Reporting by John Miller Editing by Tassilo Hummel)

0 : 0
  • narrow-browser-and-phone
  • medium-browser-and-portrait-tablet
  • landscape-tablet
  • medium-wide-browser
  • wide-browser-and-larger
  • medium-browser-and-landscape-tablet
  • medium-wide-browser-and-larger
  • above-phone
  • portrait-tablet-and-above
  • above-portrait-tablet
  • landscape-tablet-and-above
  • landscape-tablet-and-medium-wide-browser
  • portrait-tablet-and-below
  • landscape-tablet-and-below